Artificial Intelligence | Tissuepathology.com

Hamamatsu and AIxMed Announce Collaboration to Evaluate ScanPilot Integration in Cytology Research Workflows

Erica Goodpaster — Fri, 04 Sep 2026 11:32:15 +0000

Hamamatsu and AIxMed: The collaboration will allow interoperability between ScanPilot™ and NanoZoomer® scanners for technical image-quality assessment and autonomous rescanning in cytology. BRIDGEWATER, N.J., Sept. 3, 2026 /PRNewswire/ — Hamamatsu Corporation and AIxMed, a developer of software for digital cytology workflows, today announced a technical collaboration to evaluate the integration of AIxMed’s ScanPilot™ with selected Hamamatsu NanoZoomer® whole-slide scanner […]

The post Hamamatsu and AIxMed Announce Collaboration to Evaluate ScanPilot Integration in Cytology Research Workflows first appeared on Tissuepathology.com.

Hamamatsu Receives FDA 510(k) Clearance for NanoZoomer S20MD and S540MD Slide scanner systems

Erica Goodpaster — Thu, 03 Sep 2026 12:53:02 +0000

Hamamatsu: New FDA clearances expand Hamamatsu’s FDA-cleared NanoZoomer portfolio with compact benchtop and high-throughput digital pathology solutions. HAMAMATSU, Japan, Sept. 2, 2026 /PRNewswire/ — Hamamatsu Photonics K.K. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the NanoZoomer S20MD and NanoZoomer S540MD Slide scanner systems. Building on the previously […]

The post Hamamatsu Receives FDA 510(k) Clearance for NanoZoomer S20MD and S540MD Slide scanner systems first appeared on Tissuepathology.com.

Lumea: TreatmentGPS Launches Alpine Path Integration in Lumea’s Platform, Bringing AI-Powered Treatment Guidance Into Reports

Erica Goodpaster — Wed, 02 Sep 2026 12:39:17 +0000

Lumea and TreatmentGPS today announced the Alpine Path integration into Lumea’s software. LEHI, UT, UNITED STATES, September 1, 2026 /EINPresswire.com/ — Lumea, a U.S. leader in digital pathology solutions, and TreatmentGPS, a physician-built AI platform for clinical decision support and patient education, today announced the Alpine Path integration into Lumea’s software. This integration enables guideline-based treatment guidance […]

The post Lumea: TreatmentGPS Launches Alpine Path Integration in Lumea’s Platform, Bringing AI-Powered Treatment Guidance Into Reports first appeared on Tissuepathology.com.

Leica Biosystems Shares Collaboration With Mindpeak

Erica Goodpaster — Tue, 01 Sep 2026 12:36:03 +0000

From Leica Biostystems on LinkedIn: We’re excited to share the next milestone in our collaboration with Mindpeak bringing powerful AI tools closer to researchers through the Aperio AI Store. Six Mindpeak algorithms are now available on the Aperio AI Store, expanding access to AI-powered biomarker and tissue analysis applications within the Leica Biosystems digital pathology […]

The post Leica Biosystems Shares Collaboration With Mindpeak first appeared on Tissuepathology.com.

Indica Labs: Boston University Digital Pathology Core Case Study

Erica Goodpaster — Fri, 28 Aug 2026 11:50:13 +0000

From Indica Labs: No matter their organizational setting, digital pathology cores routinely provide researchers with access to advanced imaging and analysis capabilities and institutional expertise that expand the possibilities of scientific studies. The Boston University Digital Pathology Core supports researchers across BU’s Alzheimer’s Disease Research Center, Chronic Traumatic Encephalopathy Center, Boston Medical Center, and broader […]

The post Indica Labs: Boston University Digital Pathology Core Case Study first appeared on Tissuepathology.com.

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

Erica Goodpaster — Thu, 27 Aug 2026 13:04:38 +0000

Tempus’ multimodal foundation model offers diagnostic-grade precision for cancer detection and unlocks broader applications predicting biomarker status and patient prognosis CHICAGO, August 4, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced study results demonstrating that PRISM2, a multimodal slide-level pathology […]

The post Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications first appeared on Tissuepathology.com.